High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Trial Comparing MitraClip® to Surgical Therapy (HiRiDe)

High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy

The study is comparing MitraClip® to Surgical therapy in high and intermediate risk patients, who should be older than 18 years, and shall evaluate safety and efficacy of MitraClip® vs. surgery in high or intermediate risk patients. The patients will be randomised (MitraClip® or Surgery). The Study Follow-Up includes 4 visits after procedure (hospital discharge, 1, 6, 12 months post-procedure).

Study Overview

• Status: Terminated
• Conditions: Mitral Valve Insufficiency
• Intervention / Treatment: Device: MitraClip®; Procedure: Mitral valve Surgery

Detailed Description

Two-arm, multi-centre, randomised prospective study comparing MitraClip® to Surgical therapy in high and intermediate risk patients. Patients should be older than 18 years and high and intermediate risk is defined by a score (for MV repair) >= 3% and <= 10% or as determined by the local Heart Team (which should include a surgeon and a cardiologist), based on the evidence that STS risk calculator may not identify all possible risk factors. Patients are selected upon clinical conditions and severity of MR. Anatomical feasibility is assessed by ECHO, according to the IFU (information for use).

The purpose of the trial is to evaluate safety and efficacy of MitraClip® vs. surgery in high and intermediate risk patients with DMR. Study Follow-Up includes the following visits after procedure: Hospital discharge, 1, 6, 12 months post-procedure.

Primary Endpoints are the 30-day safety superiority (ITT analysis) and the 12-month efficacy non-inferiority (ITT analysis) of the MitraClip®. The overall rate of Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs) until 12 months and the MR Severity reduction at 6 and 12 month in the MitraClip® and Surgery groups are Secondary Endpoints

• Study Type: Interventional
• Enrollment (Anticipated): 294
• Phase: Phase 4

Contacts and Locations

Study Locations

• Germany
  • Bonn, Germany, 53127
    • Universitatsklinikum Bonn
  • Hamburg, Germany, 20246
    • Universitäres Herzzentrum Hamburg GmbH
  • Hamburg, Germany, 20099
    • Asklepios Klinik Hamburg St. Georg
  • Köln, Germany, 50937
    • Universitätsklinikum Köln, Herzzentrum
  • München, Germany, 81377
    • Klinikum der Universität München Großhadern
  • Siegburg, Germany, 53721
    • Helios Klinikum Siegburg
• Italy
  • Catania, Italy, 95124
    • Presidio Ospedaliero Ferrarotto Alessi
  • Milano, Italy, 20132
    • San Raffaele Hospital
  • Roma, Italy, 00133
    • Policlinico Tor Vergata
• Switzerland
  • Bern, Switzerland, 3010
    • Inselspital Bern
  • Lugano, Switzerland, 6900
    • Fondazione Cardiocentro Ticino
  • Zürich, Switzerland, 8091
    • Universitätsspital Zürich

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Gender: Both, male and female
• Minimum Age: 18 Years
• Maximum Age: no maximum age
• Severe (4+) DMR (degenerative mitral regurgitation), or 3+ DMR
• NYHA Functional Class III or IV
• Mitral valve anatomy should be suitable for both MitraClip® and Mitral valve surgery (repair or replacement)
• Subjects meet the following conditions:

Age >18 and high or intermediate risk patients with an STS calculated mortality (using the repair calculator) >=3% and <=10% or as determined by the local Heart Team (which should include a surgeon and a cardiologist), based on the evidence that STS risk calculator may not identify all possible risk factors

• patient is operable
• Signed by the subject and dated approved informed consent prior to any study related procedure
• Available and able to return to study site for post-procedural follow-up examination

Exclusion Criteria:

• Patient incapable to approve the informed consent or Emergency Cases
• functional mitral valve pathology
• evolving endocarditis or active endocarditis in the last 3 months
• heavily calcified leaflets
• subjects in whom transesophageal echocardiography is contraindicated
• subjects in whom transseptal catheterisation is contraindicated
• presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year
• currently participating in the study of an investigational drug or device
• untreated clinically significant CAD requiring revascularisation
• any percutaneous coronary, carotid, endovascular intervention or carotid surgery within 30 days or any coronary or endovascular surgery within 3 months
• prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
• concomitant and significant aortic or tricuspid valve pathology
• CVA or TIA within 6 months or severe carotid stenosis (>70% assessed by Ultrasound)
• contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately managed with premedication

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: MitraClip® Therapy; MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.	Device: MitraClip®; one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
Active Comparator: Surgery; Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard	Procedure: Mitral valve Surgery; Repair or replace mitral valve

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
30-day safety superiority (ITT analysis): Major Adverse Event Composite	The study is powered to show superiority for safety of an endovascular treatment strategy with the MitraClip® as compared to a surgical treatment strategy. The primary safety endpoint is a Major Adverse Event Composite (MAE) including all-cause death, prolonged ventilation (>48h), renal failure, stroke and need for non-elective cardiovascular or thoracic surgery (defined as any kind of cardiovascular and thoracic surgery performed within 30 days from the index procedure and non anticipated prior to the procedure). The analysis of the primary safety endpoint is a test of superiority for the proportion of subjects free from the composite of safety events in the Device vs. the Surgery group at 30 days.	30 days
12-month efficacy non-inferiority (ITT analysis): Proportion of responders in the Device vs. the Surgery group	The study is powered to show non-inferiority for clinical efficacy of an endovascular treatment strategy with the MitraClip® as compared to a surgical treatment strategy. The primary effectiveness endpoint is a test of non-inferiority for the proportion of responders in the Device vs. the Surgery group at 12 months. Patients are defined as responders if they are alive with at least a 1-grade improvement in NYHA Functional Class at 12 months over baseline and have not experienced a HF hospitalization within 12 months of randomization (MitraClip® procedure or Surgery).	12 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall rate of Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs) within 12 month	Evaluation of all SAEs and SADEs that occur during the trial	12 month
MR Severity reduction at 6 and 12 month	MR (Mitral Regurgitation) Severity reduction at 6 and 12 months in the MitraClip® and Surgery groups	between 6 and 12 month
NYHA class changes at 6 and 12 months	NYHA class changes at 6 and 12 months in the MitraClip® and Surgery groups	between 6 and 12 month
Change in 6MWT in 6 and 12 month	Change in 6MWT (6 Minute Walking Test) in 6 and 12 months in the MitraClip® and Surgery groups	between 6 and 12 months
Change in Quality of Life in 6 and 12 months	Change in Quality of Life (MLWHF) at 1,6 and 12 month in the MitraClip® and Surgery groups	between 1 and 12 months
Heart failure hospitalisation rate	Heart failure hospitalisation rate in the post randomisation in the MitraClip® and Surgery groups	during 12 months post procedure
Days alive and out of hospital	Days alive and out of hospital in the 12 months post-randomisation in the MitraClip® and Surgery groups	during 12 months post procedure
Hospital resources utilisations	Hospital resources utillizations: length of stay post-procedure, ICU beds occupancy, need for rehabilitation services	during 12 months post procedure
Change in Quality of Life (SF36) in 6 and 12 months	Change in SF36 at 1,6 and 12 month in the MitraClip® and Surgery groups	between 1 and 12 months

Collaborators and Investigators

• Sponsor: University of Zurich
• Investigators: Principal Investigator: Francesco Maisano, Prof., UniversitätSpital Zürich

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Anticipated): September 1, 2017
• Study Completion (Anticipated): September 1, 2018

Study Registration Dates

• First Submitted: August 6, 2015
• First Submitted That Met QC Criteria: August 24, 2015
• First Posted (Estimate): August 27, 2015

Study Record Updates

• Last Update Posted (Estimate): September 9, 2016
• Last Update Submitted That Met QC Criteria: September 8, 2016
• Last Verified: September 1, 2016

More Information

Terms related to this study

• Keywords: surgery; mitral regurgitation; MR; high-risk patients; DMR; MitraClip®; intermediate risk patients
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Valve Diseases; Mitral Valve Insufficiency
• Other Study ID Numbers: HiRiDe